Haemonetics

“Haemonetics reported third-quarter fiscal earnings with revenue of $339 million and adjusted earnings per share of $1.31, surpassing analyst expectations. Key segments showed mixed results, with Plasma up 3.5% and Blood Center down 19.6% due to divestitures. The company raised its full-year guidance, projecting adjusted EPS between $4.90 and $5.00 alongside improved organic growth forecasts.” … Read more